NCT03024684Active, not recruitingPhase 4
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial
Source: ClinicalTrials.gov · Last updated 12 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- First submitted
- 15 Jan 2017
- Start date
- 3 Jan 2017
- Primary completion date
- 31 Jan 2025
- Lead sponsor
- Chiayi Christian Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT03024684
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 240
- From 3 Jan 2017 to the primary completion date, 31 Jan 2025
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of CAD event (angina, unstable angina, acute myocardial infarction) or ischemic stroke
Other illness
- With other malignant disease
- Allergy to statin
Lab values
- Advanced CKD (eGFR\<30) or ESRD
Age
- Severe comorbidity with life expectancy \< 2 years
Other
- Undetermined nature of hepatic tumor
- HCC with extrahepatic metastasis or major vascular invasion
- Child Pugh score \>7
- Hyperlipidemia or other indication for statin (according to Taiwan NHI guideline)
Who the study is looking for
- Individuals with HCC BCLC stage 0 or A who received curative radiofrequency ablation or hepatic resection could be eligible.
- Individuals who had single HCC (size \> 5.0 cm) received hepatic resection would be eligible
- Individuals with prior history of HCC who had ever received curative ablation or hepatic resection without any recurrence for more than 2 years could be eligible if they had a new episode of recurrent HCC which could meet either of the former two criteria.
- After 12+/-1 weeks of curative treatment, eligible patients who have no evidence of local residual or recurrent tumors according to the dynamic CT or MRI could be enrolled
- The diagnosis of fresh HCC should be compatible with either pathological report or meet the criteria of AASLD guidelines
Age in the registry: 20 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ditmanson Medical Foundation Chiayi Christian Hospital Coordinator of this site? Confirm its status | Chiayi City | Taiwan | Unknown status |
| E-DA Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Unknown status |
| Taichung Veterans General Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
| Tainan Municipal Hospital Coordinator of this site? Confirm its status | Tainan | Taiwan | Unknown status |
| MacKay Memorial Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
| National Taiwan University Hospital Yun-Lin Branch Coordinator of this site? Confirm its status | Yunlin | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.